Charting a path toward combination therapy for Alzheimer's disease.

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Alzheimer's disease (AD) treatment progress necessitates enhanced collaboration.
• Current therapeutic strategies for AD require innovative approaches.

Purpose of the Study:

• To outline the critical need for collaborative efforts in developing combined therapeutic strategies for Alzheimer's disease.
• To highlight the importance of adaptive trial designs and biomarker integration in evaluating combination therapies.

Main Methods:

• Convened a meeting with investigators from industry, academia, and regulatory agencies.
• Discussed the necessity of combinatorial approaches and novel adaptive trial designs.
• Explored the integration of biomarkers for evaluating drug effects in combination trials.

Main Results:

• Agreement on the need for combinatorial approaches to treating AD.
• Recognition of novel adaptive trial designs incorporating biomarkers.
• Planning of a combination trial to test drugs targeting different or common pathogenic pathways.

Conclusions:

• Collaborations and consortia-based strategies are pivotal for advancing AD therapeutics.
• A recommended regulatory framework is essential for the success of combination therapy trials.
• Combined therapeutic approaches represent a promising future direction for Alzheimer's disease treatment.